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Multiple factors have improved the quality of anesthesia over the last decades, including the adoption of state-
of-the art monitoring during surgery.1 One type of monitor 
that is currently not part of standard clinical care is nocicep-
tion monitoring. Nociception is defined as the neural process 
of encoding and processing noxious stimuli (noxious stimuli 
are actually or potentially tissue damaging events), causing 
behavioral, autonomic, and hormonal responses in conscious 
and unconscious individuals.2 There are currently several 
nociception monitors available that differ in various elements, 
such as the number of variables implemented in the algo-
rithm (ranging from just one variable to a series of variables), 
the source of the variables (derived from hemodynamic or 
electroencephalographic measurements), and evidently the 
applied algorithm that results in a practical index of noci-
ception.3 We recently showed that a novel monitor, the noci-
ception level index (Medasense Biometrics Ltd., Ramat Gan, 
Israel), is a reliable measure of moderate to intense noxious 
stimulation during anesthesia and surgery.4 The nociception 
level is a multiparameter monitor that combines information 
from the finger photoplethysmogram amplitude, skin con-
ductance, skin conductance fluctuation, heart rate, heart rate 
variability, and their time derivatives into one index rang-
ing from 0 (absence of noxious stimulation) to 100 (severe 
noxious stimulation).5 The nociception level outperforms 
individual hemodynamic variables and bispectral index (BIS) 
in ability to distinguish between noxious and nonnoxious 
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Background: The multidimensional index of nociception, the nociception 
level, outperforms blood pressure and heart rate in detection of nociceptive 
events during anesthesia. We hypothesized that nociception level–guided 
analgesia reduces opioid consumption and suboptimal anesthesia events 
such as low blood pressure and use of vasoactive medication.
Methods: In this single-blinded randomized study, 80 American Society of 
Anesthesiologists class I–III adult patients of either sex, scheduled for major 
abdominal procedures under remifentanil/propofol anesthesia by target-con-
trolled infusion, were included. During the procedure nociception level, noninva-
sive blood pressure, and heart rate were monitored. Patients were randomized 
to receive standard clinical care or nociception level–guided analgesia. In the 
nociception level–guided group, remifentanil concentration was reduced when 
index values were less than 10 or increased when values were above 25 for 
at least 1 min, in steps of 0.5 to 1.0 ng/ml. Propofol was titrated to bispectral 
index values between 45 and 55. The primary outcomes of the study were 
remifentanil and propofol consumption and inadequate anesthesia events.
results: Compared with standard care, remifentanil administration was 
reduced in nociception level–guided patients from (mean ± SD) 0.119 ± 
0.033 to 0.086 ± 0.032 μg · kg-1 · min-1 (mean difference, 0.039 μg · kg-1 · 
min-1; 95% CI, 0.025–0.052 μg · kg-1 · min-1; P < 0.001). Among nociception 
level–guided patients, 2 of 40 (5%) experienced a hypotensive event (mean 
arterial pressure values less than 55 mm Hg) versus 11 of 40 (28%) patients 
in the control group (relative risk, 0.271; 95% CI, 0.08–0.77; P = 0.006). In 
the nociception level–guided group, 16 of 40 (40%) patients received vaso-
active medication versus 25 of 40 (63%) patients in the standard care group 
(relative risk, 0.64; 95% CI, 0.40–0.99; P = 0.044).
conclusions: Nociception level-guided analgesia during major abdominal 
surgery resulted in 30% less remifentanil consumption.
(ANESTHESIOLOGY 2019; 130:745–55)
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• The nociception level index (Medasense Biometrics Ltd., Ramat 
Gan, Israel), is a reliable measure of moderate to intense noxious 
stimulation during anesthesia and surgery
What This Article Tells Us That Is New
• In a randomized trial in patients having major abdominal surgery, 
compared to standard practice, nociception level-guided analgesia 
resulted in 30% less intraoperative remifentanil consumption
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stimuli.4 In an independent study, Edry et al.6 presented simi-
lar results and further showed that the nociception level out-
performed the pulse plethysmographic amplitude and the 
surgical pleth index in discriminating noxious from nonnox-
ious stimuli.
A meta-analysis (published in 2017) of randomized clin-
ical trials showed that the use of nociception monitors (i.e., 
monitors specially developed to detect moderate to severe 
nociceptive events during surgery) is associated with a reduc-
tion of movement events during anesthesia but not with other 
relevant endpoints such as a reduction in opioid consumption 
or a reduction of inadequate anesthesia events as measured by 
hemodynamic indices.3 Still some more recent and well-de-
signed studies did find advantage of nociception monitoring 
during anesthesia over standard clinical care, such as Upton et 
al.,7 who showed that fentanyl-administration guided by the 
analgesia nociceptive index during sevoflurane anesthesia for 
lumbar discectomy and laminectomy results in reduced fen-
tanyl use during surgery combined with decreased pain scores 
in the postanesthesia care unit. Sabourdin et al.8 showed that 
pupillometry-guided remifentanil administration in gyneco-
logic surgery reduced intraoperative remifentanil consump-
tion and postoperative morphine requirements.
There are currently no clinical outcome studies to assess 
whether the nociception level index impacts general anes-
thesia care during surgery, and consequently outcome stud-
ies using the nociception level index were not included in 
the aforementioned meta-analysis. We therefore designed 
a randomized controlled trial to assess the ability of noci-
ception level monitoring to modify anesthesia care during 
elective major abdominal surgery. In this first study, we 
focused on opioid consumption during anesthesia and the 
occurrence of suboptimal or inadequate anesthesia events. 
We hypothesized that nociception level monitoring com-
bines reduced opioid administration with a reduction in 
the number of inadequate anesthesia events during surgery.
Materials and Methods
Ethics
The Investigational Review Board of Leiden University 
Medical Center (Commissie Medische Ethiek, Leiden, 
The Netherlands) approved the protocol in September 
2016. The study was registered at trialregister.nl (identifier 
NTR6500) in February 2017, after which patients were 
recruited from March 2017 to December 2017. There were 
no amendments to the study protocol. All patients received 
written information about the protocol, had ample time 
to decide on their participation, and gave oral and written 
informed consent before enrollment into the study. 
Patients
American Society of Anesthesiologists (ASA) class I–III 
patients (aged 18 to 80 yr) of either sex, scheduled for 
elective major abdominal surgical, urologic, or gynecologic 
procedures under general anesthesia without epidural anal-
gesia, were recruited to participate in the study. Exclusion 
criteria included inability to give informed consent, planned 
spinal or epidural anesthesia, all forms of regional anesthe-
sia including wound infiltration, nonelective procedures, 
pregnancy or lactation, body mass index more than 35 kg/
m2, perceived difficult intubation, planned rapid sequence 
intubation, use of β-adrenergic receptor antagonists, base-
line mean arterial pressure (MAP) less than 60 mm Hg or 
more than 120 mm Hg, baseline heart rate less than 45 min-1 
or more than 90 min-1, the presence of acute preoperative 
pain, use of chronic opioid and nonopioid pain medication, 
peripheral or central nervous system disorder (including 
chronic pain), use of illicit drugs in the 30 days before sur-
gery, use of psychoactive drugs, or severe medical conditions 
(untreated or persistent peripheral or central cardiovascu-
lar disease; metabolic syndromes, including diabetes, severe 
pulmonary disease; significant hepatic disease with increased 
bilirubin, international normalized ratio, or low albumin).
Study Design
The study had a single-blinded, randomized, parallel group, 
superiority design and was performed in a single tertiary 
center. Patients were randomized to receive nociception 
level–guided analgesia or standard clinical care using a 
computer-generated randomization list by a research nurse 
not involved in the study. The randomization list was not 
available to the investigators. Patients were allocated to 
treatment just before the surgical procedure by the research 
nurse, after which the anesthesia team was informed of 
the patient’s randomization assignment. Patients were not 
informed on their group assignment and could not discern 
to what group they were allocated.
Clinical Care in Both Treatment Groups. Upon arrival in the 
operating room, the patients received an intravenous access 
line and were connected to standard monitors (3-lead 
continuous electrocardiogram, blood pressure by arm cuff, 
pulse oximetry by finger probe, neuromuscular monitor-
ing by TOF-Cuff (RGB Medical Devices, Spain), and BIS 
monitoring using the BIS forehead sensor). Additionally, all 
patients were connected to the nociception level monitor 
(PMD-200, Medasense Biometrics Ltd., Israel) via a finger 
probe that contains sensors to measure the different com-
ponents of the nociception level. The sensor was positioned 
on the middle finger of the hand contralateral to the blood 
pressure cuff. In case of nociception level–guided analgesia, 
the value of nociception level was visible and used to steer 
analgesia during surgery. In case of standard clinical care, 
the nociception level index was collected but not visible 
for clinical decision making.
None of the patients received premedication. Anesthesia 
was delivered by target-controlled infusion in which the 
target was a preset plasma concentration of propofol and 
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remifentanil. To this end, two separate infusion pumps 
(Orchestra Base Primea, Fresenius Kabi, Zeist, The 
Netherlands), one programed with the remifentanil phar-
macokinetic data set of Minto et al.9 and one programed 
with the propofol pharmacokinetic data set of Marsh et 
al.10 were used. For induction, the target plasma concen-
trations depended on the patient’s age. In patients younger 
than 65 yr the target for remifentanil was set at 4 ng/ml for 
remifentanil and 4 μg/ml for propofol; in patients 65 yr of 
age or older the target for remifentanil was set at 2.5 ng/ml 
and 2.5 μg/ml for propofol. After consciousness was lost (as 
detected by BIS values below 60, absence of eyelash reflex, 
and no response to verbal stimulation), rocuronium 0.6 mg/
kg was administered and the trachea of the patient was 
intubated when the TOF-cuff measured zero twitches. The 
ventilator settings were such that end-tidal PCO
2
 was kept 
at 4.5 ± 0.4 vol.% (34 ± 3 mm Hg). After intubation the tar-
get propofol concentration was adjusted in steps of 0.5 μg/
mL to ensure a steady state in the value of the BIS at 50 ± 
5. The train-of-four target was 1 ± 1; additional rocuronium 
could be administered as deemed necessary. The remifent-
anil target concentration was set to zero 5 to 10 min before 
the end of surgery. At the end of surgery, all patients with 
train-of-four ratios less than 0.9 were reversed with sugam-
madex 2 mg/kg and extubated when the train-of-four ratio 
exceeded 0.9, the patient was breathing and awake. If the 
train-of-four ratio was 0.9 or greater no reversal agent was 
administered. In both treatment groups, fluid administration 
was standardized to 5 to 6 ml/min. Additional fluids could 
be administered in case of moderate to severe blood loss.
Each patient received preemptive treatment for postop-
erative pain: acetaminophen 1 g 30 min before surgery and 
intravenous morphine 0.15 to 0.20 mg/kg, 45 to 60 min 
before the end of surgery. In the postanesthesia care unit 
(PACU) additional intravenous morphine doses could be 
given. These morphine doses were based on the postop-
erative pain scores (pain scores were obtained using an 
11-point numerical rating scale from 0 [no pain] to 10 [most 
severe pain imaginable]): in case of pain scores greater than 4 
morphine bolus doses of 1 or 2 mg could be given at 5-min 
intervals until pain was reduced below a numerical rating 
scale of 4.
Standard Clinical Care Group. When hemodynamic changes 
outside of the normal range were observed, our standard 
clinical care was as follows. In case of high blood pressure 
(systolic blood pressure greater than 140 mm Hg) or tachy-
cardia (heart rate greater than 90 min-1), the remifentanil 
infusion is increased; in case of concurrent high BIS values 
(greater than 55), the propofol infusion is increased. In case 
of low blood pressure (mean arterial pressure less than 60 mm 
Hg), initially, the remifentanil infusion is lowered (lowest 
target plasma concentration that was allowed is 1 ng/ml), 
and in case of concurrent low BIS values (less than 45) the 
propofol infusion is lowered as well. Next, vasoconstrictors 
may be given (a continuous infusion of norepinephrine, or 
bolus doses of  ephedrine or phenylephrine). Only when 
blood pressure remains low additional crystalloids are given. 
Adaptations in remifentanil target-controlled infusion are 
performed in steps of 0.5 to 1.0 ng/ml. There are no restric-
tions in the timing of the changes in remifentanil or propo-
fol targets. Finally, in case of bradycardia (heart rate less than 
30 min-1), atropine may be given. All of these adaptations 
(such as the magnitude of remifentanil/propofol changes in 
target concentration, the dose of vasoactive medication, the 
amount of fluids given) are at the discretion of the attend-
ing anesthesiologist.
Nociception Level–guided Analgesia Group. In the noci-
ception level–guided group the remifentanil target was 
adjusted to maintain a nociception level value between 10 
and 25. In case the nociception level decreased less than 10 
for more than 60 s, remifentanil target-controlled infusion 
levels were lowered in steps of 0.5 ng/ml, whereas in case 
of a values greater than 25 for more than 60 s, remifen-
tanil target-controlled infusion levels were increased in 
steps of 0.5 (nociception level increase remained less than 
45) or 1.0 ng/mL (nociception level increase greater than 
45). A nociception level cutoff value of 20 yields specific-
ity and sensitivity values of 80% and 73%, respectively, for 
discrimination between nonpainful and painful stimuli.4 
A somewhat wider nociception level window was applied 
for a less rigid and possible unstable use of the nocicep-
tion level. After the target-controlled infusion value was 
changed, 5 min were allowed before a next change was 
made. The lowest remifentanil target permitted was 1 ng/
ml. If the target remifentanil concentration of 1 ng/mL 
was reached (at nociception level values less than 10) and 
the patient was hypotensive, vasoactive medication (ephed-
rine, phenylephrine, norepinephrine, atropine) could be 
administered. Atropine was administered when heart rate 
decreased less than 30 min-1. Because the nociception level 
may be sensitive to such medication, nociception level val-
ues were then not used for at least 5 min to guide analge-
sia, with the exception of norepinephrine as this drug was 
given as continuous infusion.
The Nociception Monitor
The nociception level has been described previously.4–6 In 
brief, the nociception level is a composite score derived 
from a set of physiologic variables (i.e., peripheral effec-
tors of the autonomous nervous system): heart rate, heart 
rate variability, amplitude of the photoplethysmogram, skin 
conductance, skin conductance variability, and the time 
derivatives of these variables. High nociception level levels 
can be explained by higher sympathetic activity. The noci-
ception level ranges from 0 to 100, which correlates with 
reference clinical scores of nociception based on estimated 
opioid concentration and nociceptive stimulus strengths as 
determined in previous studies.4–6 The device received EU 
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and Health Canada certification but still has not received 
U.S. Food and Drug Administration clearance.
Data Collection
Data were derived from three sources: (1) the nociception 
level monitor, (2) the BIS monitor, (3) and the electronic 
medical record database (Healthcare Information X-change, 
Chipsoft, The Netherlands). All monitors were time-aligned 
before induction of anesthesia. Various events occurring 
during anesthesia were annotated in the nociception level 
monitor such as drug administration (including targets and 
doses) and surgical and anesthesia events (e.g., loss of con-
sciousness, intubation, incision, end of surgery, eye opening, 
start and end of anesthesia; end of anesthesia is defined by 
spontaneous ventilation after extubation). Hemodynamic 
parameters (MAP, heart rate) were collected from the elec-
tronic medical record. In case of evident occurrences of 
artefacts in blood pressure or heart rate that were observed 
during the case, a note in the case record form was made 
and the data were excluded from the analysis. Finally, in the 
PACU, we queried the patients for indications of memory 
of surgery/awareness (using the Brice questionnaire)11 and 
obtained pain scores at 30-min intervals.
Primary and Secondary Study Endpoints
The study had the following primary endpoints: remifentanil 
and propofol use during anesthesia and inadequate anesthe-
sia events. Per protocol, inadequate anesthesia events were 
defined by12: (1) use of vasoactive medication (ephedrine, 
phenylephrine, norepinephrine, atropine); (2) hypotension: 
MAP less than 55 mm Hg (severe hypotension) or MAP less 
than 60 mm Hg (moderate hypotension); (3) hypertension: 
occurrence of systolic blood pressure greater than 140 mm 
Hg; (4) bradycardia: heart rate less than 45 min-1; and (5) 
occurrence of tachycardia: heart rate greater than 90 min-1.
Secondary endpoints were (1) time from reversal of relax-
ant to extubation; (2) occurrence of awareness; (3) pain scores 
in the PACU; (4) morphine use in the PACU; and (5) level 
of sedation in the PACU. Sedation was measured according 
to the Leiden Observers’ Assessment of Alertness and seda-
tion score, a 7-point scale ranging from normal alertness 
(score = 0) to unrousable to painful stimuli (score = 6).13
Statistical Analysis
Because this study is the first to assess nociception  level– 
guided analgesia, we remained unknown on effect sizes and 
SDs. Using the results from a study on a different nociceptive 
tool,13 we assumed that remifentanil use is 0.21 μg · kg-1 · min-1 
in the standard clinical care group and 0.14 μg · kg-1 · min-1 
in nociception level–guided group, a SD of 0.08, 1-beta = 0.9 
and alpha = 0.05, 37 patients were required per group. For 
practical purposes, we used 40 patients per group.
Primary endpoints remifentanil and propofol con-
sumption were analyzed by independent two-tailed t tests; 
inadequate anesthesia events were analyzed by χ2 test with 
relative risks calculated from the 2 × 2 contingency tables. 
Secondary endpoints were analyzed by independent two-
tailed t test or Mann–Whitney U test depending on the type 
of data and data distribution. The analyses were restricted to 
data related to the primary and secondary endpoints. Data 
are presented as mean ± SD, median and interquartile range, 
or frequency; P values less than 0.05 were considered signif-
icant. Data analysis was performed using GraphPad Prism 
version 7.00 for macOS (GraphPad Software, United States).
results
A total of 150 patients were approached for participation 
in the study. Forty-two patients either refused participa-
tion or were not randomized because their surgery was 
rescheduled for logistic reasons. Twenty-eight subjects were 
recruited to train the research team in the use of the noci-
ception level; these data were discarded. Following train-
ing, eighty subjects (40 in each group) were randomized 
and completed the study. Patient characteristics (age, sex, 
body mass index, ASA classification, baseline hemodynam-
ics) are given in table 1. The age distribution was similar 
between groups with 16 patients aged 65 yr or older in 
both treatment arms. Surgery types were similar between 
nociception level–guided and standard clinical care groups: 
urology (48%), abdominal surgery (39%), and gynecology 
(14%). Surgical procedure and anesthesia times were similar 
between treatment groups (data not shown). The average 
nociception level, blood pressure, heart rate, and BIS val-
ues observed during the course of anesthesia are given in 
figure 1. All study patients completed the trial without any 
harms or adverse events, and there we no missing data.
table 1. Baseline Patient Characteristics and Surgeries in the 








M/F, n 20/20 24/16
Age, yr 59 (22–79) 59 (20–81)
Weight, kg 80 ± 16 81 ± 15
Height, cm 174 ± 9 176 ± 9
BMI, kg.m-2 26 ± 4 26 ± 3
Heart rate, mn-1* 75 ± 10 77 ± 15
MAP, mm Hg* 103 ± 12 99 ± 10
ASA class 1/2/3, n





Urology, n (%) 19 (47) 19 (47)
General surgery, n (%) 15 (38) 16 (40)
Gynecology, n (%) 6 (15) 5 (13)
All values are represented as mean ± SD, median (interquartile range), or numbers 
(n). ASA, American Society of Anesthesiologists; BMI, body mass index; F, female; 
M, male; and MAP, mean arterial pressure.
*Values obtained at patient screening in the preoperative clinic.
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Remifentanil and Propofol Consumption
To control for patient weight and duration of surgery, we 
report the anesthesia drug doses as dose · kg-1 · min-1 of anes-
thesia time. The intraoperative remifentanil administration 
was less in the nociception level–guided group compared 
with standard clinical care by 28%: nociception level–guided 
0.086 ± 0.032 μg · kg-1 · min-1 (mean ± SD) versus standard 
clinical care 0.119 ± 0.033 μg · kg-1 · min-1 (mean differ-
ence 0.039 μg · kg-1 · min-1 with 95% CI 0.025 to 0.052 μg · 
kg-1 · min-1, unpaired t test P < 0.001; fig. 2, panels A and B). 
Propofol administration did not differ between treatments: 
nociception level–guided 0.105 ± 0.022 mg · kg-1 · min-1 
versus standard clinical care 0.107 ± 0.025 mg · kg-1 · min-1, 
mean difference 0.003 mg · kg-1 · min-1 with 95% CI −0.012 
to 0.017 mg · kg-1 · min-1, P = 0.715).
Inadequate Anesthesia Events
Vasoactive Medication. In the standard clinical care group, 
25 of 40 (63%) patients received either one vasoactive 
(n = 16 of 40, 40%) or at least two vasoactive (n = 9 of 
40, 23%) drugs (norepinephrine, ephedrine, phenylephrine, 
or atropine). In contrast, in the nociception level–guided 
group 16 of 40 (40%) received vasoactive medication, of 
which just 3 of 40 (8%) received more than one drug. In 
comparison to standard care, the relative risk of receiving 
at least one vasoactive drug was 0.64, 95% CI, 0.40–0.99, 
P = 0.044 (table 2).
Blood Pressure. Two of 40 (2 of 40, 5%) patients in the noci-
ception level–guided group experienced a single hypoten-
sive event with MAP values less than 55 mm Hg, whereas 
11 of 40 patients (28%) in the standard clinical care group 
experienced at least one such an event (relative risk, 0.271; 
95% CI, 0.08–0.77; P = 0.006). Nine of 40 patients (23%) 
in the nociception level–guided and 17 of 40 (43%) in the 
standard clinical care group experience a MAP less than 
60 mm Hg event (relative risk, 0.53; 95% CI, 0.27–1.02; 
P = 0.055). See figure 3 for the distribution of the duration 
of these hypotensive events. There were no differences in 
hypertensive events between treatment groups. Sixteen of 
40 (nociception level; 40%) and 12 of 40 (standard clini-
cal care; 30%) patients experienced episodes with systolic 
blood pressure greater than 140 mm Hg (relative risk, 1.33; 
Fig. 1. Average nociception level (index; A), bispectral index (B), heart rate (HR; C), and mean arterial pressure (MAP; D) values observed at 
baseline (awake), loss of consciousness, intubation, end of anesthesia, and eyes open. Data are given for the total population (blue symbols), 
nociception level–guided (orange squares), and standard clinical care (dark red squares). Comparisons shown are for the total population. 
Values are mean ± 95% CI.
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Fig. 2. (A) Individual remifentanil doses (in μg · kg-1 · min-1) and mean values (orange bars) in the two treatment groups (P < 0.001). 
(B) Cumulative remifentanil consumption (μg/kg) during the first 2 h of anesthesia. Red symbols, standard clinical care; dark green symbols, 
nociception level–guided analgesia.
table 2. Vasoactive Medication
 nociception Level–guided Standard clinical care
P value dose n (%) dose n (%)
Ephedrine, mg 10 ± 5 6 (15) 9 ± 5 13 (33)  
Phenylephrine, μg 275 ± 133 6 (15) 200 ± 140 12 (30)  
Atropine, mg   0.8 ± 0.4 2 (5)  
Norepinephrine, μg 130 ± 55 7 (18) 166 ± 59 6 (15)  
Number of patients receiving at least one drug  16 (40)  25 (63) 0.044*
Values are mean ± SD. 
*Relative risk, 0.64; 95% CI, 0.40–0.99.
Fig. 3. Number of patients and duration of hypotensive events in standard clinical practice and nociception level–guided patients with a 
mean arterial pressure (MAP) cutoff of 55 mm Hg (A; P = 0.006) and 60 mm Hg (B; P = 0.055).
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95% CI, 0.74–2.46; P = 0.348). No patients in the nocicep-
tion level–guided group had both hypotensive (MAP less 
than 55 mm Hg) and hypertensive (systolic blood pressure 
greater than 140 mm Hg) events against 4 of 40 patients 
(10%) in the standard clinical care group (relative risk, 0; 
95% CI, 0–0.91; P = 0.040).
Heart Rate. None of the patients that received nocicep-
tion level–guided analgesia experienced a heart rate below 
45 min-1 against 5 of 40 (13%) in the standard clinical care 
group (relative risk, 0; 95% CI, 0–0.73; P = 0.021). In the 
nociception level–guided group, 7 of 40 (18%) patients 
versus 6 of 40 (15%) patients in the standard clinical care 
patients had a heart rate greater than 90 (relative risk, 1.17; 
95% CI, 0.45–3.07; P = 0.762).
Secondary Endpoints
The median time between reversal of the relaxant to extu-
bation differed between treatment groups: nociception 
level–guided group (n = 25) 7 min with interquartile range 
4 to 10 min versus standard clinical care-group (n  =  31) 
9 min with interquartile range 7 to 13.5 min (difference 
between medians, −2 min; 95% CI, −5–0 min; P = 0.027). 
In both groups there were no patients who reported aware-
ness during anesthesia. Intraoperative morphine doses were 
0.19 ± 0.04 mg/kg and 0.18 ± 0.04 mg/kg in nociception 
level–guided and standard clinical care groups, respectively 
(mean difference, 0.01 mg/kg; 95% CI, −0.01–0.03 mg/kg; 
P = 0.237), as defined in the protocol. See table 3 for obser-
vations made in the PACU. There were no differences in 
pain scores, opioid treatment for pain, and sedation scores.
Nociception Level Events
Nociception Level Less Than 10. All subjects had at least one 
event during anesthesia with nociception level values less 
than 10. 
Nociception Level Greater Than 25. Thirty-three (83%) and 35 
(88%) patients in standard clinical care and nociception lev-
el–guided groups, respectively, experienced a nociception 
level–value greater than 25 during anesthesia. The frequency 
and time spent at high nociception level values differed 
between treatment groups: nociception level values greater 
than 25 occurred at least 10 times in 9 (23%) standard clin-
ical care patients versus 2 nociception level–guided patients 
(5%); nociception level values greater than 45 and greater 
than 60 occurred in 17 (nociception level–guided; 43%) versus 
14 patients (standard clinical care; 35%), and 5 (nociception 
level–guided; 13%) versus 2 patients (standard clinical care; 5%), 
respectively. In none of the patients a nociception level value 
above 70 occurred. Figure 4 gives the distribution of nocicep-
tion level values for the first 2 h of anesthesia (fire plots of the 
5-s output of the nociception level device).
Finally, the amount of crystalloids (normal saline or 
Ringer’s lactate solution) was similar between treatments. The 
median (interquartile range) volume given in nociception lev-
el–guided group was 850 (613 to 1,200) ml versus in the stan-
dard clinical care group 1,000 (638 to 1,125) ml. The median 
(interquartile range) PACU stay did not differ between groups: 
53 (36 to 72) min and 61 (44 to 78) min in the nociception 
level and standard clinical care groups, respectively.
discussion
The main observations from our randomized clinical trial 
are that nociception level monitoring is associated with 30% 
reduction in the use of remifentanil combined. These results 
indicate that nociception level monitoring during anesthe-
sia has certain advantages in terms of opioid consumption. 
We did not find any differences in propofol requirements 
during anesthesia or differences in early postoperative out-
come measures such as postoperative pain or opioid con-
sumption in the PACU.
Opioid Consumption
We calculated that the difference in remifentanil dose 
resulted in a 33% lower target plasma remifentanil concen-
tration: average remifentanil target plasma concentration 
during nociception level–guided anesthesia 2.4 ng/ml versus 
3.6 ng/ml during standard clinical care. These are clinically 
relevant differences. Apparently, because of the use of the 
monitor the anesthesiologist is more attentive and proactive 
in keeping the nociception level between threshold values 
according to protocol, whereas in the standard clinical care 






Mean difference or  
Median difference (95% ci) P value
Morphine consumption, mg/kg 0.06 ± 0.06 [40] 0.06 ± 0.06 [40] 0.01 (−0.02 to 0.03) 0.661
Maximum pain score 6 (4–7) [40] 5 (3–7) [40] 1 (−1 to 1) 0.590
Pain upon arrival in PACU 5 (2–6) [40] 2.5 (0–6) [40] 2.5 (0–2) 0.242
Pain after 30 min 5 (4–6) [35] 4.5 (3–6) [36] 0 (−1 to 1) 0.761
Pain after 60 min 4 (3–5) [14] 4 (3–5.5) [15] 0 (−1 to 1) 0.926
Sedation score (0–6) upon arrival in PACU 2 (1–2) [40] 1 (0.25–2) [40] 1 (0–1) 0.075
All values are represented as mean ± SD (morphine consumption) or median (interquartile range). Pain scores are verbal rating scores ranging from 0 (no pain) to 10 (most severe 
pain imaginable). The sedation score is the Leiden Observers’ Assessment of arousal/sedation.13 PACU, postanesthesia care unit.
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group the approach to adjust the target-controlled infu-
sion level might have been less aggressive because of the 
lack of continuous monitoring of nociceptive events. Five 
percent of patients in the nociception level–monitored 
group experienced a hypotensive event with MAP values 
less than 55 mm Hg whereas 28% in the standard clinical 
care group experienced at least one such event (relative 
risk, 0.271; 95% CI, 0.08–0.77; P = 0.006). According to 
our post hoc type-1 error correction (see item 9 in Study 
Limitations), further studies with larger sample sizes are 
needed to address whether nociception monitoring results 
in improved hemodynamic stability. Severe hypotension is 
not uncommon, and even short durations are associated 
with poor outcomes such as acute kidney and myocardial 
injury.14 During their stay in our clinic none of our patients 
developed any major complications. Still, we did not follow 
our patients beyond their hospital stay and hence remain 
uninformed on possible long-term complications.
Secondary Endpoints
We relate the observed 2-min difference in time between 
rocuronium reversal and extubation between the two treat-
ment groups to the lower plasma remifentanil concentra-
tion in nociception level–guided patients and consequently 
an earlier onset of spontaneous respiration. As we previ-
ously showed, breathing activity is initiated when remifen-
tanil plasma concentrations drop to about 2 ng/ml.15,16 We 
observed no differences in pain scores and morphine con-
sumption in the PACU (table 3). This could be related to 
the inability of the nociception level to impact postopera-
tive events when using short-acting opioids or to the use 
of preemptive morphine treatment. Because the rapid drop 
in remifentanil plasma concentration may be associated with 
high pain levels, we administered 0.15 to 0.2 mg/kg mor-
phine to all of our patients, irrespective of treatment group, 
40 to 60 min before the end of surgery. This may have obfus-
cated any effect of the lower remifentanil dosing in the noci-
ception level–guided patient population on postoperative 
pain scores. These findings are in agreement with the major-
ity of studies using nociception monitoring during anesthesia 
that show no difference in postoperative pain scores despite 
reduced opioid administration during surgery (but not all, 
see articles by Upton et al. and Sabourdin et al.)7,8,12,17–20 In 
one study in children,21 the use of the surgical pleth index 
during fentanyl/sevoflurane anesthesia was associated with 
increased postoperative pain scores and an increase in the 
proportion of patients with high emergence agitation scores, 
whereas the use of fentanyl during anesthesia was reduced by 
Fig. 4. Distribution of nociception level values during nociception level–guided analgesia (A) and during standard clinical care (B). The colors 
represent the percentage of patients ranging from dark blue (0%) to dark red (30%); see legend bars. The data are the 5-s outputs of the 
nociception level device. The data are aligned at intubation (t = 0 min). In the nociception level–guided group more patients fall in the desig-
nated limits of nociception level 10 to 25 as apparent by more light blue to yellow color; the equal amounts of dark blue and dark red are the 
manifestation of no difference between groups in nociception level values less than 10 and greater than 25.
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about 75%. However, this study might not have been optimal 
to demonstrate clinical benefits of the nociception monitor 
as the procedures were short (adenotonsillectomies) and the 
opioid used was fentanyl with a relatively long duration of 
action. Irrespective, these as well as our observations point 
directly to the need to be cautious in the extreme lowering 
of opioid administration and the need for a predefined lowest 
permitted opioid target during anesthesia as well as relaxed 
lower monitor thresholds as otherwise there may be insuffi-
cient opioid carryover effect from anesthesia to recovery.
Nociception Level Thresholds
We based the lower nociception level threshold (i.e., the 
nociception level value below which remifentanil infusion 
was lowered) on the results of our previous study in which 
we observed that low nociception level values (less than 10) 
were associated with absence of nociception.4 It is import-
ant to realize that low nociception level values (less than 10) 
may occur under three circumstances: (1) in the presence of 
noxious stimuli when patients are treated with high doses 
of opioids; (2) in the absence of noxious stimuli in patients 
treated with (relatively) high dose opioids; or (3) in the 
absence of noxious stimuli with low dose analgesic treat-
ment. In the latter case a sudden noxious (surgical) stim-
ulus applied by the surgeon will cause a nociception level 
increase above the upper threshold (i.e., nociception level 
greater than 25) because these patients then lack appropri-
ate analgesics coverage. Hence, we advise to dose the anal-
gesic medication not purely based on the nociception level 
thresholds but also on the anticipated nociceptive input.
Study Limitations
The study has several limitations. (1) In common with all 
studies on the influence of nociception monitor-guided 
anesthesia on various anesthesia endpoints, our study was 
single blinded. This may have influenced the outcome due 
to an implementation or performance bias. (2) We cannot 
exclude a learning effect in our study. Possibly the knowledge 
gained when treating nociception level–guided patients may 
have been used in some way when giving anesthesia to the 
standard clinical care group. Whether this offsets a possible 
implementation bias is not known. (3) We relied on intermit-
tent blood pressure measurements to guide anesthesia in the 
standard clinical care group. It may well be that a continuous 
blood pressure signal from an arterial line may have improved 
our ability to guide anesthesia with more rapid response to 
nociceptive input.4,6 We are unaware of any studies comparing 
nociception monitors with continuous blood pressure moni-
toring in their ability to adequately and promptly detect noci-
ceptive stimuli. (4) As discussed earlier, there is no agreement 
on the use of specific thresholds in nociception monitoring. 
Some of our results will evidently alter when different (wider) 
thresholds are applied. (5) We excluded patients using β- 
adrenergic receptor antagonists. This exclusion is somewhat 
arbitrary and based on the idea that such medication may alter 
the performance of the nociception level. However, current 
clinical use of the nociception level index in our hospital does 
not support this assumption and shows that the nociception 
level behaves similarly in patients using β-adrenergic receptor 
antagonists. Still, this needs to be confirmed under controlled 
conditions.22 (6) We were cautious in using the nociception 
level to guide anesthesia following administration of vaso-
constrictors or atropine (with the exception of norepineph-
rine) because these drugs may influence the performance of 
the nociception level monitor. It is our experience that just 
a short window (up to 5 min) is needed before nociception 
level–guidance may be continued. (7) Standard clinical care 
differs across medical centers. Our standard clinical care (tar-
get-controlled infusion propofol/target-controlled infusion 
remifentanil/low threshold use of norepinephrine) makes 
generalizability of our results challenging. We will next study 
whether similar results are obtained with the more common 
anesthesia practice of anesthesia with intermittent sufentanil 
administration and sevoflurane maintenance. (8) We argue 
that only when the nociception level monitor is used as 
part of standard clinical care we can eventually assess its true 
added value with respect to long-term outcome measures.
Finally (9), we did not apply preplanned type-1 error 
control, which is a major limitation given the multiple end-
points (remifentanil/propofol consumption and five inad-
equate anesthesia events). We therefore performed post hoc 
Bonferroni corrections. After correction the level of signif-
icance was set at P < 0.05/2 = 0.025 for drug consumption 
and P < 0.05/2 for inadequate anesthesia events. A second 
correction for remifentanil and propofol consumption was 
applied (P < 0.025/2 = 0.0125) and for single inadequate 
anesthesia events (P < 0.025/5 = 0.005). This resulted in a 
significant difference between treatments after correction for 
remifentanil consumption (P < 0.001). Severe hypotensive 
events (P = 0.006) just failed to reach the level of significance.
Conclusions
We studied the influence of nociception-guided anesthesia 
using the nociception level monitor and observed that, com-
pared with standard clinical care, nociception level guidance 
resulted in about 30% less remifentanil use during anesthesia. 
Nociception level monitoring had no effect on postopera-
tive pain scores or postoperative opioid requirements.
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Melotte’s Nitrous Oxide Ad…That Subtracted: More Than 
Vague about That Sprague!
An inventive dentist, Dr. George Washington Melotte (1836 to 1915) held eight United States patents, but 
he had no patentee rights to the nitrous oxide generator depicted (left) in his 1870 newspaper advertisement. 
Melotte had cropped out most of the gasometer from the diagram that originally accompanied the 1868 pat-
ent of A. W. Sprague. (Hopefully, Melotte was actually using a Sprague apparatus in his office in Ithaca, New 
York!) Thirty-seven years after not being challenged for “borrowing” Sprague’s diagram, Melotte considered 
himself challenged by his own mailman. Only the mailbag saved the postal employee from what was deemed 
Melotte’s “temporary insanity” while lunging with a ceremonial sword. (Copyright © the American Society 
of Anesthesiologists’ Wood Library-Museum of Anesthesiology.)
George S. Bause, M.D., M.P.H., Honorary Curator and Laureate of the History of Anesthesia, Wood Library-Museum 
of Anesthesiology, Schaumburg, Illinois, and Clinical Associate Professor, Case Western Reserve University, Cleveland, 
Ohio. UJYC@aol.com.
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